Innovative and passionate; that's how we describe our biotech companies. From cutting-edge biopharmaceutical therapies to bioinformatics, we support our clients’ pursuit of excellence. Through their relentless drive to innovate, we work to protect pivotal intellectual property, navigate regulatory environments, and advise on financing strategy.
Industry Highlights
Celebrating our founders’successes
2000
Illumina Completes IPO Worth $96 Million
Diagnostics & Research
2009
Genentech Acquired by Roche for $46.8 Billion
Pharmaceuticals
2010
Pacific Biosciences Raises $200 Million in IPO
Diagnostics & Research
2014
Xenon Pharmaceuticals Launches IPO
Drug Discovery, Pharmaceuticals
2016
BioCardia Unveils Reverse Merger
Pharmaceuticals
2017
Denali Therapeutics Makes Record BioTech IPO
Drug Discovery
2018
WuXi AppTec Raises $356 Million IPO
Diagnostics & Research
2018
Allakos Completes IPO Worth $135 Million
Drug Discovery, Pharmaceuticals
2019
IGM Biosciences Launches IPO
Biotechnology
2020
Applied Molecular Transport Closes IPO at $154 Million
Pharmaceuticals
2020
ORIC Pharmaceuticals Raises $138 Million IPO
Pharmaceuticals
2020
ALX Oncology Holdings Inc. Closes IPO at $186 Million
Immuno-Oncology
2021
Kinnate Biopharma Inc. Raises $276 Million IPO
Drug Discovery, Pharmaceuticals
2021
Tenaya Therapeutics Completes IPO Worth $207 Million
We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content. For more information or to opt-out, visit our privacy policy.